SavedAdd your journal

Journals / Journal of Clinical and Analytical Medicine / 2012 / Cilt: 3 - Sayı: 3

Yaşlı ileri evre küçük hücreli dışı akciğer kanserli hastalarda paklitaksel ve karboplatin

Paclitaxel and carboplatin in elderly patıents with advanced non-small cell lung cancer

Erdem ÇUBUKCU
Mustafa CANHOROZ
Osman MANAVOĞLU
Savaş AKSOY
Özkan KANAT
Nihan ALKIŞ
Sinem ÇUBUKCU
Oya KARADAĞ
Pages
293–295
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The median overall survival time and progression-free survival time was 13 months and 8.5 months, respectively.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: In this study, the safety and tolerability of paclitaxel and carboplatin (PC) regimen in elderly patients with advanced non-small cell lung cancer (NSCLC) was investigated.
📊
Key Findings & Data:Material and Method: Elderly patients (ages ≥70 years) who received PC for stage III (n=11) or IV (n=34) NSCLC were evaluated retrospectively.
💡
Conclusion & Impact:The median overall survival time and progression-free survival time was 13 months and 8.5 months, respectively.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Aim: In this study, the safety and tolerability of paclitaxel and carboplatin (PC) regimen in elderly patients with advanced non-small cell lung cancer (NSCLC) was investigated. Material and Method: Elderly patients (ages ≥70 years) who received PC for stage III (n=11) or IV (n=34) NSCLC were evaluated retrospectively. Results: There were 43 males and 2 females, with a median age of 75.5 (range, 70-82). The response rate was 40%. The median overall survival time and progression-free survival time was 13 months and 8.5 months, respectively. One-year survival rate was 51%. Treatment was well tolerated by the patients. The most frequent side effect observed was grade 3 or 4 neutropenia (57.7%). There was no treatment-related death. Discussion: PC regimen may be a good alternative for the treatment of elderly patients with advanced NSCLC.

Özet

Amaç:Bu çalışmada, ileri evre yaşlı küçük hücreli dışı akciğer kanseri (KHDAK) hastalarında, paklitaksel ve karboplatin (PK) rejiminin etkinliği ve tolerabilitesi araştırıldı. Gereç ve Yöntem: Evre IIIB (n=11) veya IV (n=34) KHDAK nedeniyle PK tedavisi alan yaşlı (yaş ≥ 70) 45 hasta retrospektif olarak değerlendirildi. Bulgular: Hastaların 43’ü erkek, 2’si kadın olup ortanca yaşı 75.5 (70-82) idi. Yanıt oranı %40’dı. Medyan genel sağkalım süresi ve progresyonsuz sağkalım süresi sırasıyla 13 ay ve 8.5 ay, 1-yıllık sağkalım oranı %51’di. Tedavi hastalar tarafından iyi tolere edildi. Grade 3 veya 4 nötropeni (%57.7) en sık görülen yan etkiydi. Tedaviye bağlı ölüm görülmedi. Sonuç: PK rejimi ileri evre yaşlı KHDAK hastalarının tedavisi için iyi bir alternatif olabilir.

🔖

Cite This Article

ÇUBUKCU, E., CANHOROZ, M., MANAVOĞLU, O., AKSOY, S., KANAT, Ö., ALKIŞ, N., ÇUBUKCU, S., KARADAĞ, O. (2022). Yaşlı ileri evre küçük hücreli dışı akciğer kanserli hastalarda paklitaksel ve karboplatin. Journal of Clinical and Analytical Medicine, Cilt: 3 - Sayı: 3, 293–295. https://ajindex.com/articles/551967

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Weinmann M, Jeremic B, Toomes H, Friedel G, Bamberg M. Treatment of lung cancer in the elderly. Part I: non-small cell lung cancer. Lung Cancer 2003;39(3):233-53
  2. Pallis AG, Gridelli C, van Meerbeeck JP, Greillier L, Wedding U, Lacombe D, et al. EORTC Elderly Task Force and Lung Cancer Group and International Society for Geriatric Oncology (SIOG) experts’ opinion for the treatment of non-small-cell lung cancer in an elderly population. Ann Oncol 2010;21(4):692-706
  3. Belani CP. Paclitaxel/carboplatin in the treatment of non-small cell lung cancer.Oncology (Williston Park) 1998;12(1 Suppl 2):74-9
  4. Belani CP. Paclitaxel and docetaxel combinations in non-small cell lung cancer.Chest 2000;117(4 Suppl 1):144S-151S
  5. Okamoto I, Moriyama E, Fujii S, Kishi H, Nomura M, Goto E, et al. Phase II study of carboplatin-paclitaxel combination chemotherapy in elderly patients with advanced non-small cell lung cancer. Jpn J Clin Oncol 2005;35(4):188-94
  6. Inoue A, Usui K, Ishimoto O, Matsubara N, Tanaka M, Kanbe M, et al. A phase II study of weekly paclitaxel combined with carboplatin for elderly patients with advanced non-small cell lung cancer. Lung Cancer 2006;52(1):83-7
  7. Sakakibara T, Inoue A, Sugawara S, Maemondo M, Ishida T, Usui K, et al. Randomized phase II trial of weekly paclitaxel combined with carboplatin versus standard paclitaxel combined with carboplatin for elderly patients with advanced nonsmall-cell lung cancer. Ann Oncol 2010;21(4):795-9
  8. Ramalingam S, Perry MC, La Rocca RV, Rinaldi D, Gable PS, Tester WJ, et al. Comparison of outcomes for elderly patients treated with weekly paclitaxel in combination with carboplatin versus the standard 3-weekly paclitaxel and carboplatin for advanced nonsmall cell lung cancer. Cancer 2008;113(3):542-6
  9. Gridelli C, Perrone F, Gallo C, Cigolari S, Rossi A, Piantedosi F, et al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 2003;95(5):362-72
  10. Fidias P, Supko JK, Martins R, Boral A, Carey R, Grossbard M, et al. A phase II study of weekly paclitaxel in elderly patients with advanced non-small cell lung cancer. Clin Cancer Res 2001;7(12):3942-9
  11. Hainsworth JD, Burris HA 3rd, Litchy S, Morrissey LH, Barton JH, Bradof JE, et al. Weekly docetaxel in the treatment of elderly patients with advanced nonsmall cell lung carcinoma. A Minnie Pearl Cancer Research Ne